Neuroimaging biomarkers for Alzheimer’s disease in asymptomatic APOE4 carriers.

Le 02 Nov 2021

Auteur : Chételat G, Fouquet M

Année : 2013

Journal : Rev Neurol (Paris) 0035-3787

PubMed Id : 24016463

The E4 allele of the apolipoprotein E (APOE4) is the major known genetic risk factor for Alzheimer’s disease (AD), with a dramatic increase in the risk of developing AD as the number of APOE4 alleles increases from 0 to 2. For this reason, asymptomatic APOE4 carriers as a group offer a great opportunity to search for the presence of early biomarkers for AD. The present article reviews neuroimaging studies on APOE4 carriers, focusing on cognitively normal individuals and on the main neuroimaging biomarkers for AD, i.e. atrophy with structural MRI, hypometabolism with FDG-PET, and amyloid deposition with amyloid-PET imaging.